Safety of opicapone use in Parkinson’s disease: review of literature and real-world safety data
Parkinson's disease (PD) presents a significant global health concern with increasing prevalence and burden. This review article examines the safety data of drug Opicapone from literature and real-world sources of safety data, highlighting the need for vigilance over anti-parkinsonian drugs. For literature review, the PubMed database was mined which concluded that Opicapone, a selective COMT inhibitor for PD, demonstrated ADR like dyskinesia, nausea, vomiting, headache, and constipation where on the other hand real-world evidence showed no safety alerts or recalls initiated by regulatory authorities for Opicapone, but known risks like dyskinesia and hallucination were identified. However, clinical trial statistics revealed hypertension as the most probable ADR, alongside constipation, dizziness, dyskinesia, headache, somnolence, and hyperhidrosis. Whereas, unlisted events, such as somnolence, hyperhidrosis, pulmonary embolism, and abdominal pain, were also observed. Most ADRs belonged to the nervous system disorders and gastrointestinal disorders class which can be attributed to the pharmacological effect of Opicapone. It was concluded from this review that there is need for continuous safety vigilance for Opicapone use as despite the presence of well-structured safety guidance, new risks can emerge.
2. Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23(5 Suppl):S83-92.
3. Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clin Geriatr Med. 2020;36(1):1-12.
4. Dorsey E, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1): S3-S8.
5. Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease. Parkinsonism RelatDisord. 2012;18(4):321-326.
6. Svetel M, Tomić A, Kresojević N, Kostić V. Pharmacokinetic drug evaluation of opicapone for the treatment of Parkinson’s disease. Expert Opin Drug MetabToxicol. 2018;14(3):353-360.
7. Jagadeesan AJ, Murugesan R, Vimala Devi S, Meera M, Madhumala G, Padmaja MV, et al. Current trends in etiology, prognosis and therapeutic aspects of Parkinson’s disease: a review. Acta Bio Med. 2017;88(3):249.
8. Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson's syndrome. Ann Rev Pathol Mech Dis. 2023; 18:95-121.
9. Aryal S, Skinner T, Bridges B, Weber JT. The pathology of Parkinson’s disease and potential benefit of dietary polyphenols. Molecules. 2020;25(19):4382.
10. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013;3(4):461-491.
11. Troncoso-Escudero P, Parra A, Nassif M, Vidal RL. Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease. Front Neurol. 2018; 9:860.
12. Jankovic J, Tan EK. Parkinson’s disease: Etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91(8):795-808.
13. Ye, Hui, Laurie A. Robak, Meigen Yu, Matthew Cykowski, and Joshua M. Shulman. "Genetics and pathogenesis of Parkinson's syndrome." Annual Review of Pathology: Mechanisms of Disease 18 (2023): 95-121.
14. Latif S, Jahangeer M, Razia DM, Ashiq M, Ghaffar A, Akram M, El Allam A, Bouyahya A, Garipova L, Shariati MA, Thiruvengadam M. Dopamine in Parkinson's disease. Clinicachimica acta. 2021 Nov 1; 522:114-26.
15. Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, Srikumar PS. Alpha-Synuclein Aggregation in Parkinson's Disease. Frontiers in Medicine. 2021; 8:736978.
16. Moon HE, Paek SH. Mitochondrial Dysfunction in Parkinson's Disease. Experimental Neurobiology. 2015;24(2):103-116.
17. McGeer PL, McGeer EG. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism & Related Disorders. 2004;10(Suppl 1): S3-S7.
18. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathologica. 2012;124(2):153-172.
19. Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation. Movement Disorders. 2021;36(1):25-36.
20. Jankovic J. Parkinson's disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2008;79(4):368-376.
21. Abusrair AH, Elsekaily W, Bohlega S. Tremor in Parkinson's Disease: From Pathophysiology to Advanced Therapies. Tremor and Other Hyperkinetic Movements. 2022; 12:29.
22. Ferreira-Sánchez MDR, Moreno-Verdú M, Cano-de-la-Cuerda R. Quantitative Measurement of Rigidity in Parkinson´s Disease: A Systematic Review. Sensors (Basel). 2020;20(3):880.
23. Bologna M, Paparella G, Fasano A, Hallett M, Berardelli A. Evolving concepts on bradykinesia. Brain. 2020;143(3):727-750.
24. Viseux FJF, Delval A, Defebvre L, Simoneau M. Postural instability in Parkinson's disease: Review and bottom-up rehabilitative approaches. Neurophysiology and Clinics. 2020;50(6):479-487.
25. Cosgrove J, Alty JE, Jamieson S. Cognitive impairment in Parkinson's disease. Postgraduate Medical Journal. 2015;91(1074):212-220.
26. Tan LC. Mood disorders in Parkinson's disease. Parkinsonism & Related Disorders. 2012;18(Suppl 1):S74-S76.
27. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson's disease. Journal of Neurology. 1998;245(Suppl 1): S15-S18.
28. Chen Z, Li G, Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiology of Disease. 2020; 134:104700.
29. Cury RG, Galhardoni R, Fonoff ET, Perez Lloret S, Dos Santos Ghilardi MG, Barbosa ER, Teixeira MJ, Ciampi de Andrade D. Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. European Journal of Pain. 2016;20(2):151-165.
30. Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent Advances in Drug Therapy for Parkinson's Disease. Internal Medicine. 2023;62(1):33-42.
31. Zahoor I, Shafi A, Haq E. Pharmacological Treatment of Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018. Chapter 7. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536726/
32. Gandhi KR, Saadabadi A. Levodopa (L-Dopa). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482140/
33. Alonso Cánovas A, LuquinPiudo R, García Ruiz-Espiga P, Burguera JA, Campos Arillo V, Castro A, Linazasoro G, López Del Val J, Vela L, Martínez Castrillo JC. Dopaminergic agonists in Parkinson's disease. Neurologia. 2014;29(4):230-241.
34. Dezsi L, Vecsei L. Monoamine Oxidase B Inhibitors in Parkinson's Disease. CNS Neurol Disord Drug Targets. 2017;16(4):425-439.
35. Fabbri M, Ferreira JJ, Rascol O. COMT Inhibitors in the Management of Parkinson's Disease. CNS Drugs. 2022;36(3):261-282.
36. Barrett MJ, Sargent L, Nawaz H, Weintraub D, Price ET, Willis AW. Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe? Movement Disorders Clinical Practice. 2021;8(8):1181-1188.
37. Laroche ML, Gautier S, Polard E, Rabier MB, Chouchana L, Lebrun-Vignes B, Faillie JL, Petitpain N, Lagarce L, Jonville-Bera AP; IATROSTAT study group. Incidence and preventability of hospital admissions for adverse drug reactions in France: A prospective observational study (IATROSTAT). British Journal of Clinical Pharmacology. 2023;89(1):390-400.
38. World Health Organization: WHO. Parkinson disease. [Online] Available at: https://www.who.int/news-room/fact-sheets/detail/parkinson-disease [Accessed on 24 May 2023]
39. Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Frontiers in Public Health. 2021; 9:776847.
40. Willis AW, Roberts E, Beck JC, et al. Incidence of Parkinson disease in North America. npj Parkinson's Disease. 2022; 8:170.
41. Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology.2018;17:939–953.
42. Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI, Porcelli P, D'Antuono M, Castiglione NG, Adams A, Furlan G, Grisoni I, Hall S, Boga L, Mancini V, Ciuca M, Chonzi D, Edwards B, Mangoni AA, Tuccori M, Prokofyeva E, De Gregorio F, BertazzoliGrabinskiBroglio M, van Leeuwen B, Kruger P, Rausch C, Le Louet H. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Therapeutic Advances in Drug Safety. 2021; 12:20420986211038436.
43. Feldman M, Margolesky J. Opicapone for the treatment of Parkinson’s disease: a review. International Journal of Neuroscience. 2021;1-11.
44. Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimarães B, Rocha JF, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. European Journal of Neurology. 2019; 26:953–960.
45. Kwak N, et al. Efficacy and safety of opicapone for motor fluctuations as an adjuvant to levodopa therapy in patients with Parkinson’s disease: A systematic review and meta-analysis. Journal of Parkinson's Disease. 2022;12(3):773–783.
46. Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimarães B, Rocha JF, Soares‐da‐Silva P. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson's disease. Movement Disorders. 2022;37(11):2272-2283.
47. Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N. Randomized, controlled study of opicapone in Japanese Parkinson's patients with motor fluctuations. Movement Disorders. 2021;36(2):415-423.
48. Takeda A, Takahashi R, Tsuboi Y, Nomoto M, Maeda T, Nishimura A, Yoshida K, Hattori N. Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations. Journal of Neural Transmission. 2021;128(3):337-344.
49. Nomoto M, et al. Effect of opicapone tablets on levodopa and 3-O-methyldopa pharmacokinetics in healthy Japanese subjects: Phase 1 study. Clinical Pharmacology in Drug Development. 2021;10(2):180-189.
50. Reichmann H, et al. Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study. Translational Neurodegeneration. 2020;9(1).51. Lopes N, Ferreira J, Lees A. Evaluation of impulse of control disorders in fluctuating Parkinson’s disease patients under opicapone treatment. Movement Disorders. 2016;31(2).
51. Lopes N, Ferreira J, Lees A. Evaluation of impulse of control disorders in fluctuating Parkinson’s disease patients under opicapone treatment. Movement Disorders. 2016;31(2).
52. Ferreira JJ, et al. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. 2018;90(21): e1849–e1857.
53. Rocha JF, et al. Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics: Opicapone effect on levodopa PK. British Journal of Clinical Pharmacology. 2017;83(3):540–553.
54. Lees AJ, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: A randomized clinical trial. JAMA Neurology. 2017;74(2):197.
55. Rocha JF, et al. Effect of 3 single-dose regimens of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor response in patients with Parkinson disease. Clinical Pharmacology in Drug Development. 2016;5(3):232-240.
56. Ferreira JJ, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. The Lancet Neurology. 2016;15(2):154-165.
57. Pinto R, l'Hostis P, Patat A, Homery MC, Falcão A, Nunes T, Rocha JF, Soares-da-Silva P. Evaluation of opicapone on cardiac repolarization in a thorough QT/QTc study. Clinical Pharmacology in Drug Development. 2015;4(6):454-462.
58. Ferreira JJ, et al. Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. European Journal of Neurology. 2015;22(5):815-e56.
59. Rocha JF, et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. European Journal of Clinical Pharmacology. 2014; 70:1059-1071.
60. Rocha JF, et al. Opicapone: a short-lived and very long-acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects: Pharmacokinetic/dynamic profile of opicapone after repeated doses. British Journal of Clinical Pharmacology. 2013;76(5):763-775.
61. Almeida L, et al. Pharmacokinetics, pharmacodynamics and tolerability of opicapone, a novel catechol-O-methyltransferase inhibitor, in healthy subjects: prediction of slow enzyme-inhibitor complex dissociation of a short-living and very long-acting inhibitor. Clinical Pharmacokinetics. 2013;52(2):139-151.
62. Heads of Medicines Agencies: RMP. (2022, September). CMDH List of Safety Concerns per Approved Risk Management Plan (RMP) of Active Substances per Product (September 2022).
63. Ema (2022b). Risk management plans - European Medicines Agency. [Online] Available at: https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pharmacovigilance/risk-management/risk-management-plans.
64. Swissmedic, C. (2020) RMP summaries. Available at: https://www.swissmedic.ch/swissmedic/en/home/humanarzneimittel/market-surveillance/risk-management--psurs--pv-planning-/rmp-summaries.html#opicapone.
65. Summary of Product Characteristics: Ongentys (opicapone) oral capsules. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002790/WC500209536.pdf
66. EMA (2018) Ongentys, European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ongentys (Accessed: July 17, 2023).
67. Administration, T.G. (2022) Australian Public Assessment Reports (AUSPAR). Available at: https://www.tga.gov.au/resources/auspar?keywords=opicapone.
68. CTG labs - NCBI (2023). Available at: https://clinicaltrials.gov/.
69. Coleman JJ, Pontefract SK. Adverse drug reactions. Clinical Medicine (London). 2016;16(5):481-485.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.